A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
We are asked patients to take part in this study because they had recurrent (returned) (1st
or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM).
The purposes of this study are:
- To see if Sutent has any change on the patient and their cancer.
- To see if Sutent will slow or stop the growth of their tumor.
- To measure the safety of Sutent. Sutent is Food and Drug Administration (FDA) approved
to treat patients with a gastrointestinal stromal tumor after the disease worsened while
taking another medicine called imatinib mesylate or when imatinib mesylate cannot be
taken. Sutent is also FDA approved to treat patients with advanced renal cell carcinoma.
At this time, it is not known whether Sutent will improve symptoms, or help patients
with this disease live longer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute